首页|转移性结直肠癌抗EGFR治疗耐药机制研究进展

转移性结直肠癌抗EGFR治疗耐药机制研究进展

Review of research progress on mechanism of resistance to anti-EGFR therapy in metastatic colorectal cancer

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
转移性结直肠癌(mCRC)是结直肠癌进展的晚期阶段,治疗选择多样,但患者预后通常不佳.表皮生长因子受体(EGFR)信号通路在mCRC的发展中扮演核心角色,涉及多个关键分子.EGFR异常活化与肿瘤生长、转移及治疗耐药紧密相关.因此,EGFR靶向治疗对mCRC至关重要,但治疗耐药常常导致治疗失败,且分子机制复杂.在此,笔者综述mCRC抗EGFR治疗耐药的相关分子机制及干预研究进展,为深入理解抗EGFR耐药机制,优化治疗策略提供参考.
Metastatic colorectal cancer(mCRC)represents the advanced stage of colorectal cancer progression.Treatment options are diverse,but patient prognosis is generally poor.The epidermal growth factor receptor(EGFR)signaling pathway plays a central role in the development of mCRC,involving multiple key molecules.Abnormal activation of EGFR is closely related to tumor growth,metastasis,and treatment resistance.Therefore,EGFR-targeted therapy is crucial for mCRC,but treatment resistance often leads to therapy failure,and the molecular mechanisms are complex.Here,the authors review the molecular mechanisms related to anti-EGFR treatment resistance in mCRC and the progress in intervention studies,providing a reference for a deeper understanding of the mechanisms of anti-EGFR resistance and the optimization of treatment strategies.

Colorectal NeoplasmsNeoplasm MetastasisErbB ReceptorsMolecular Targeted TherapyDrug Resistance,Neo-plasmReview

徐昆明、许云华、陈锡光、付广、黄秋林、肖帅

展开 >

南华大学附属第一医院胃肠外科,湖南衡阳 421001

南华大学附属第一医院肿瘤疾病研究所,湖南衡阳 421001

结直肠肿瘤 肿瘤转移 ErbB受体 分子靶向治疗 抗药性,肿瘤 综述

湖南省自然科学基金资助项目湖南省自然科学基金资助项目湖南省卫生健康委员会科研基金资助项目湖南省卫生健康委员会科研基金资助项目

2022JJ305382023JJ6036820201919202104010105

2024

10.7659/j.issn.1005-6947.2024.06.016

中国普通外科杂志
中南大学

中国普通外科杂志

CSTPCD北大核心
影响因子：1.623
ISSN：1005-6947
年,卷(期)：2024.33(6)
  • 134